Chemotherapy combination regimens for EGFR-TKI resistant metastatic EGFR-mutated NSCLC: A systematic review and network meta-analysis

被引：0
|
作者：
Qin, B. [1 ]
Jiao, X. [1 ]
Liu, K. [1 ]
Zang, Y. [1 ]
机构：
[1] Shanghai Changzheng Hosp, Dept Med Oncol, Shanghai, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.10.697
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
664P
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Feasibility and safety of EGFR-TKI neoadjuvant therapy for EGFR-mutated NSCLC: A meta-analysis
    Zhuchen Yu
    Fei Xu
    Juntao Zou
    European Journal of Clinical Pharmacology, 2024, 80 : 505 - 517
  • [2] Feasibility and safety of EGFR-TKI neoadjuvant therapy for EGFR-mutated NSCLC: A meta-analysis
    Yu, Zhuchen
    Xu, Fei
    Zou, Juntao
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 80 (04) : 505 - 517
  • [3] Clinical advances in EGFR-TKI combination therapy for EGFR-mutated NSCLC: a narrative review
    Zhang, Qianru
    Wang, Ruo
    Xu, Lu
    TRANSLATIONAL CANCER RESEARCH, 2023, 12 (12) : 3764 - 3778
  • [4] Safety of Readministration of EGFR-TKI After Onset of Interstitial Lung Disease in Advanced EGFR-Mutated NSCLC: A Systematic Review and Meta-Analysis
    Kashizaki, Fumihiro
    Chen, Hao
    Miyasaka, Atsushi
    Tsuchiya, Nanami
    Yamada, Chihiro
    Okazaki, Shunsuke
    Kaneko, Mai
    Kano, Taiki
    Kameda, Yohei
    Kikuchi, Akitomo
    Yumoto, Kentaro
    Osawa, Hiroyuki
    Koizumi, Harumi
    Takahashi, Kenichi
    Kaneko, Takeshi
    CLINICAL LUNG CANCER, 2024, 25 (01) : e52 - e57.e2
  • [5] EGFR-TKI plus /- Antiangiogenics for EGFR-mutated Advanced NSCLC
    da Silva, L. L.
    Matsas, S.
    Aguiar, P., Jr.
    Taveira, G. M. T.
    Barcelos, I. F.
    Lopes, G. L., Jr.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S416 - S417
  • [6] First-line concomitant EGFR-TKI plus chemotherapy versus EGFR-TKI alone for advanced EGFR-mutated NSCLC: a meta-analysis of randomized phase III trials
    Landre, Thierry
    Assie, Jean-Baptiste
    Chouahnia, Kader
    Des Guetz, Gaetan
    Auliac, Jean-Bernard
    Chouaid, Christos
    EXPERT REVIEW OF ANTICANCER THERAPY, 2024, 24 (08) : 775 - 780
  • [7] Association between BIM deletion polymorphism and clinical outcome of EGFR-mutated NSCLC patient with EGFR-TKI therapy: A meta-analysis
    Ma, Ji-Yong
    Yan, Hai-Jun
    Gu, Wei
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2015, 11 (02) : 397 - 402
  • [8] EGFR-TKI Plus Brain Radiotherapy Versus EGFR-TKI Alone in the Management of EGFR Mutated NSCLC Patients with Brain Metastases: A Meta-Analysis
    Xia, X.
    Guo, M.
    He, J.
    Liang, W.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S382 - S382
  • [9] EGFR-TKI plus brain radiotherapy versus EGFR-TKI alone in the management of EGFR-mutated NSCLC patients with brain metastases
    Dong, Kai
    Liang, Wenhua
    Zhao, Shen
    Guo, Minzhang
    He, Qihua
    Li, Caichen
    Song, Haiqing
    He, Jianxing
    Xia, Xiaojun
    TRANSLATIONAL LUNG CANCER RESEARCH, 2019, 8 (03) : 268 - +
  • [10] EGFR-TKI Combined with Pemetrexed versus EGFR-TKI Monotherapy in Advanced EGFR-Mutated NSCLC: A Prospective, Randomized, Exploratory Study
    Gu, Weiguang
    Zhang, Hua
    Lu, Yiyu
    Li, Minjing
    Yang, Shuang
    Liang, Jianmiao
    Ye, Zhijian
    Li, Zhihua
    He, Minhong
    Shi, Xiaoliang
    Wang, Fei
    You, Dong
    Gu, Weiquan
    Feng, Weineng
    CANCER RESEARCH AND TREATMENT, 2023, 55 (03): : 841 - 850
12345